Xiamen Humanity Hospital
Chondrosarcoma treatment cost in China typically relies on a combination of surgical intervention and advanced radiation. A major surgical procedure such as bone resection runs from $9,500 to $22,500, while specialized proton therapy runs from $36,500 to $47,500. Total expenses depend on the tumor stage, surgical complexity, and specific technology used. Patients often save 45% to 85% compared to US medical costs in cities like Guangzhou, Beijing, and Xiamen.
Typical Chondrosarcoma Treatment Costs in China
Bookimed Expert Insight: Advanced stage patients benefit from centers specializing in minimally invasive technologies. Fuda Cancer Hospital offers specialized cryosurgery and NanoKnife therapies, treating over 30,000 international patients. For cases requiring complex multidisciplinary management, Xiamen Humanity Hospital provides comprehensive tertiary care with 47 clinical departments. Those needing high-precision radiation should consider specialists like Professor Liu Shi Xin. He is an expert in VMAT and SBRT at JCI-accredited facilities.
| China | Turkey | Austria | |
| Proton-beam therapy | from $36,500 | from $1,500 | from $80,000 |
| Proton therapy for prostate cancer | from $42,500 | from $30,000 | from $80,000 |
| Proton therapy for breast cancer | from $38,500 | from $30,000 | from $55,000 |
| Chemotherapy for breast cancer | from $14,800 | from $1,200 | from $15,000 |
| Bone resection | from $9,500 | from $5,000 | from $25,000 |
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
Chondrosarcoma treatment in China primarily focuses on wide surgical resection to ensure clear margins. Major centers utilize limb-sparing techniques, 3D-printed implants, and advanced particle therapy. For inoperable cases, specialists apply local ablation technologies like NanoKnife and cryosurgery to target tumors precisely.
Bookimed Expert Insight: Patient volume serves as a critical quality indicator in China. Fuda Cancer Hospital has treated over 30,000 international patients. Large-scale centers like Xiamen Humanity Hospital manage around 1,000,000 patients annually. This massive case volume allows Chinese surgeons to gain exceptional experience with rare subtypes over a short period.
Patient Consensus: Patients emphasize the need for expert pathology reviews because tumor grade determines the entire surgical plan. Choosing between limb-sparing surgery and amputation remains the most significant decision for those with extensive disease.
Advanced or high-grade chondrosarcomas in China are treated primarily through aggressive surgical resection using limb-salvage techniques. Surgeons aim for wide en-bloc removal to ensure negative margins. Integrated care models often combine surgery with high-energy particle therapy and specialized minimally invasive ablation for complex or late-stage cases.
Bookimed Expert Insight: While many facilities offer basic oncology, specialized centers like Fuda Cancer Hospital demonstrate higher capability for complex cases. They treat over 30,000 international patients using niche technologies like vascular interventional therapy and microwave hyperthermia. This high volume suggests that centers with localized ablative tools are often better equipped for patients with recurrent or hard-to-reach tumors.
Patient Consensus: Patients note it is critical to find a multidisciplinary sarcoma team because these tumors often resist standard chemotherapy. They emphasize that achieving clean surgical margins during the first procedure is the most important factor for long-term success.
China is home to prominent hospitals specializing in chondrosarcoma treatment. Institutions like Fuda Cancer Hospital and Xiamen Humanity Hospital lead in surgical and interventional oncology. These centers offer advanced orthopedic oncology surgery. They use 3D-printed reconstructions and targeted ablation therapies for complex bone malignancies.
Bookimed Expert Insight: Patient volume often signals where the highest level of specialized expertise lies. While Fuda Cancer Hospital serves over 30,000 international patients, Xiamen Humanity Hospital treats around 1,000,000 patients annually. Large-scale institutions like these often house the most experienced surgeons. They are more likely to successfully manage rare cases like chondrosarcoma.
Patient Consensus: Patients note that finding a dedicated orthopedic oncology team is more important than hospital prestige. They emphasize that regular pathology reviews are vital. These can change the tumor grade and completely alter treatment plans.
In China, the five-year survival rate for chondrosarcoma patients ranges between 75% and 80%. Long-term outcomes for ten years remain high at approximately 60%. These metrics represent the highest survival outcomes among all primary malignant bone tumors managed within the country.
Bookimed Expert Insight: Patients should prioritize tertiary facilities like Xiamen Humanity Hospital or JCI-accredited Fuda Cancer Hospital. Large centers in China manage massive volumes. Xiamen Humanity Hospital alone treats 1,000,000 patients annually. This high frequency with complex cases often leads to better preservation of limb function.
Patient Consensus: Patients emphasize that low-grade tumors feel like a chronic manageable condition. They note that getting a second pathology opinion is vital because initial biopsies are often incomplete.
Traditional Chinese Medicine (TCM) serves strictly as supportive care for chondrosarcoma. It does not cure the tumor. Surgical resection remains the primary medical standard. Chinese oncology centers integrate acupuncture and herbal tonics to manage pain, nausea, and immune stability during recovery.
Bookimed Expert Insight: Patients Choosing Chinese centers like Fuda Cancer Hospital often prioritize its JCI-accredited integration of minimally invasive techniques. While many seek TCM, the real value lies in combining it with advanced cryosurgery or NanoKnife. This approach targets tumors while using traditional methods only to boost post-operative recovery speed.
Patient Consensus: Patients emphasize that TCM should never delay surgery. They note it is most helpful for regaining appetite and managing stress during the recovery phase.